In Simple Terms
Scientists have found a way to make medicines safe for pregnant women by ensuring they don’t harm the baby. They did this by combining antibodies with a special protein, so the medicine reaches the mother but not the baby. This breakthrough means pregnant women can get the treatment they need without risking their child’s health.
Breakthrough in Drug Development
Researchers have discovered a method to develop biological drugs that can be safely used during pregnancy. By combining antibodies with a specific protein, they can reduce the drug’s transfer to the fetus through the bloodstream, protecting the baby while maintaining the treatment’s effectiveness for the mother.
A recent study conducted by a team from the University of Oslo and Oslo University Hospital, in collaboration with local and international colleagues, demonstrated the potential to design biological drugs that are safe during pregnancy without harming the fetus. These drugs use antibodies combined with albumin to minimize placental transfer.
Understanding Placental Transfer
The study revealed a unique relationship between antibodies and albumin in the blood. Although neonatal receptors for antibodies (FcRn) bind to both antibodies and albumin, they differentiate between them when transporting substances to the fetus. The placenta selectively transfers antibodies while keeping albumin out of this pathway.
Researchers conducted experiments on mice and human tissues outside the body to illustrate this phenomenon. The results showed that integrating antibodies with albumin can limit drug transfer to the fetus, reducing potential negative effects on children.
Challenges and Proposed Solutions
Pregnant women with chronic illnesses face significant challenges when choosing appropriate treatments. Biological drugs like monoclonal antibodies are increasingly used to treat chronic diseases, but their use during pregnancy has been limited due to potential risks to the fetus.
Thanks to a better understanding of placental mechanisms, it is now possible to design drugs that offer long-term effectiveness and safety during pregnancy. Doctors can now use these medications without worrying about their impact on the fetus.
Practical Applications and Future Potential
The new model was tested on human placental tissues and in disease models, such as autoimmune thrombocytopenia in mice, where results showed a significant reduction in fetal drug exposure. This paves the way for developing new biological drugs that combine safety and effectiveness.
This study not only enhances our understanding of how the placenta works but also provides tangible solutions for developing drugs that meet the needs of pregnant women. The focus now shifts to further research to better control protein transfer across the placenta.
Conclusion
These discoveries highlight enormous potential in designing safe and effective biological drugs for use during pregnancy. By understanding how the placenta functions, scientists can develop treatments that minimize risks to the fetus while providing necessary therapies for the mother. This marks a significant advancement in maternal and fetal health care, opening new horizons in the field of biological drugs.